WhaleCreepWhat the best hedge funds own, from their SEC 13F filings
HomeFundsRA Capital Management › Q3 2010

RA Capital Management 13F holdings, Q3 2010

Holdings as of September 30, 2010 · filings on SEC EDGAR · latest filing →

RA Capital Management disclosed 18 US equity positions worth $101.4m in its Q3 2010 13F filing. The largest position was BSTC at 16.6% of the reported book, followed by ARTHROCARE CORP and ALXN. Against the Q1 2010 filing, it opened 9 new positions, added to 5 and reduced 4 among the top 18 holdings.

← Q1 2010 · Q4 2010 →

What did RA Capital Management own in Q3 2010? Top 18 positions

#StockSectorWeightValueSharesΔ sharesvs Q1 2010
1 BSTC BIOSPECIFICS TECHNOLOGIES CO 16.6%$16.8m624,917 2% added
2 ARTHROCARE CORP 10.0%$10.1m373,292 15% added
3 ALXN ALEXION PHARMACEUTICALS INC 9.6%$9.7m151,300 4% added
4 PHARMASSET INC 8.3%$8.4m285,261 -13% reduced
5 JAZZ PHARMACEUTICALS INC 8.1%$8.2m767,670 new
6 VALEANT PHARMACEUTICALS INTL 7.6%$7.7m306,200 new
7 ALLERGAN INC 7.2%$7.3m109,200 new
8 DEPOMED INC 5.9%$6.0m1,337,582 -54% reduced
9 UTHR UNITED THERAPEUTICS CORP DEL Healthcare 5.5%$5.5m98,700 -24% reduced
10 CELG CELGENE CORP 4.8%$4.9m84,600 new
11 CUBIST PHARMACEUTICALS INC 4.7%$4.8m203,100 new
12 CYPRESS BIOSCIENCES INC 3.8%$3.9m1,000,000 167% added
13 AASTROM BIOSCIENCES INC 2.5%$2.5m1,644,838 62% added
14 SEQUENOM INC 2.4%$2.5m350,000 new
15 MAP PHARMACEUTICALS INC 1.1%$1.1m75,000 new
16 PSIVIDA CORP 1.0%$1.0m231,300 -75% reduced
17 NPS PHARMACEUTICALS INC 0.7%$684.0k100,000 new
18 VISION--SCIENCES INC DEL 0.3%$298.0k250,679 new

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.